Last Updated On 4/28/2025 6:50:10 PM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.
| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: UpToDate |
| Recipient: You |
| Company: Clinical Care Options |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Chugai Pharmaceutical Co. |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Genetech Inc. |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Jazz Pharmaceuticals |
| Recipient: You |
| Company: Puma Biotechnology |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Boehringer Ingelheim |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Jazz Pharmaceuticals |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Molecular subtyping of small cell lung cancer to predict therapeutic responses (US Patent No.: 11,732,306; Priority Date 9/3/2019; Issue Date 8/22/2023) |
| Recipient: You |
| Please describe: Methods and systems for diagnosis, classification, and treatment of small cell lung cancer and other high grade neuroendocrine carcinomas (Priority date: 3/3/2021) |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|